Genetic Heterogeneity and Molecular Convergence Pathways of Autism Spectrum Disorder: From Genetic Risk Discovery to Integration of Neurobiological Mechanisms

Zhihui Wang *

Shanghai Pinghe School, Shanghai, 201206, China

* Corresponding Author Email: wangzhihui@shphschool.com

Abstract. Autism Spectrum Disorder (ASD) presents with multiple clinical and genetic features. Genomic research during the last ten years has discovered numerous risk genes which include rare high-impact mutations together with common polygenic variants. The various cell types in the brain show different genetic and developmental patterns yet research indicates that multiple genetic disruptions lead to common biological pathways which control synaptic function and chromatin remodeling and ion channel signaling and immune regulation. The study of single-cell and spatial transcriptomics has revealed new information about how these processes occur at specific times and in particular cell types which shows that mid-fetal corticogenesis is a crucial developmental period and that excitatory projection neurons are particularly vulnerable. Scientists conduct maternal immune activation studies to determine how environmental disturbances create identical molecular pathways. This paper focuses on ASD through its genetic heterogeneity and convergent pathways and synaptic dysfunction and precision diagnosis, establishes a framework which connects genetic diversity to common neurobiological effects through the combination of genetic information with transcriptomic data and developmental analysis to create a basis for ASD precision medicine. The model would function as a guiding structure to lead biomarker research and patient classification and intervention development through analysis of personal molecular and developmental patterns.

Keywords: Autism Spectrum Disorder, Genetic Heterogeneity, Convergent Pathways, Synaptic Dysfunction, Precision Diagnosis.

1. Introduction

Autism spectrum disorder (ASD) is used to describe a clinically heterogeneous group of neurodevelopmental disorders that share common behavioral core features affecting social communication and include restrictive and repetitive stereotypic behavioral patterns and interests. The condition affects people of all racial backgrounds and economic levels and impacts vital life functions which include social and work activities and produces permanent effects. Historically ASD has been linked to three main clinical features which include speech problems and social interaction deficits and repetitive or restricted behaviors. The symptoms of ASD include aggression and hyperactivity and impulsivity and psychological or physiological co-morbidities such as anxiety and depression [1]. ASD prevalence has been rising worldwide since the last few decades because of expanded diagnostic standards and better healthcare access and rising public understanding of the condition. According to CDC data and international autism prevalence studies, the chart shows a steady global increase in ASD diagnoses over the past 15 years. In the United States, ASD prevalence rose dramatically, from about 11.3 per 1,000 children in 2010 to nearly 28.7 per 1,000 in 2025. In Europe, the prevalence increased more moderately, from 7.9 to 14.5 per 1,000, showing a similar upward trend though at a lower rate than the U.S. In East Asia, including regions such as China, Japan, and South Korea, reported rates also rose, from 4.2 to 11.4 per 1,000, likely due to growing recognition of ASD and expanding research attention in recent years. Overall, the trend indicates a global rise in ASD identification, with the U.S. showing the highest prevalence, followed by Europe, and then East Asia [2].

The field has made great progress while ASD origins continue to present multiple complex factors that scientists have not fully understood: The wide range of ASD symptoms and common co-

occurring conditions make it difficult to discover single disease mechanisms and apply genetic findings to develop diagnostic tools and treatments. The disorder shows both genetic and clinical diversity, however, researchers have identified multiple molecular and developmental patterns which affect common biological pathways during specific developmental stages. Research findings indicate that ASD genetic diversity leads to specific mutations which affect shared biological pathways during development. The absence of one CHD8 gene copy leads to widespread gene expression changes in human neural progenitors and cerebral organoids which disrupt synapse formation and neural differentiation and axon guidance and chromatin regulation. Research on CHD8 in animals reveals that prefrontal cortex circuits develop abnormally which disrupts both excitatory and inhibitory neural activity and synaptic communication and functional network connections during development [3].

This paper investigates how genetic diversity affects the shared biological mechanisms that exist in ASD. The study of genetic diversity effects on neurobiological results enables researchers to understand ASD pathophysiology which guides the creation of specific therapeutic approaches. The following sections will examine ASD core features and genetic heterogeneity and convergent pathways to establish a framework for using genetic information in clinical practice.

2. Genetic Heterogeneity of ASD and Its Influencing Factors

The genetic heterogeneity of ASD results from multiple factors including rare genetic variants and common genetic variants and sex-linked protective factors and environmental influences. The discovery of hundreds of risk genes through genomic progress has not solved the problem of understanding how genetic variations affect disease expression because of the complex ways genes work and how they are passed down through generations and how they respond to environmental factors. Future research needs to combine population diversity with biological sex and environmental context in multi-omics frameworks to establish a precision-medicine approach for autism through mechanistic understanding.

2.1. Genetic Architecture: Rare Variants and Common Polygenic Risk

The medical community identifies ASD as a neurodevelopmental condition which shows strong genetic links because of its complex nature. Twin research demonstrates genetic influence through its findings because monozygotic twins possess 70-90% identical genes yet dizygotic twins only share 0-10% of their genetic material [4]. The condition tends to cluster within families because younger male siblings of autistic individuals face an increased chance of developing autism. Research indicates ASD exists as a genetically diverse condition because it develops from rare genetic variants together with common polygenic risk factors. Research conducted over the past twenty years has led scientists to discover various genetic elements which influence the development of ASD. Genomic technology has made significant progress through whole-exome sequencing (WES) and genome-wide association studies (GWAS) and copy number variants (CNVs) analyses which have led to an increasing number of genes being associated with ASD. The research has identified both rare genetic mutations that cause major effects and common genetic variations with small effects which together explain the intricate genetic structure of ASD.

The large-scale sequencing research has found hundreds of genes linked to ASD through de novo mutations and CNVs and common inherited genetic variations. The Simons Foundation Autism Research Initiative (SFARI) database contains more than 1,000 candidate genes which they organize into confidence levels starting from "syndromic" to “suggestive” [5]. The three high-confidence loci CHD8, SHANK3 and MECP2 have different molecular pathways which lead to synaptic development and chromatin remodeling. Rare variants in the genome tend to create significant functional changes which commonly damage genes that play a crucial role in brain development. The de novo loss-of-function (LoF) mutations in SHANK3 synaptic scaffolding gene result in Phelan-McDermid syndrome which is a syndromic form of ASD that causes intellectual disability and speech problems [6]. Research findings show that CHD8 gene mutations lead to abnormal brain development

and macrocephaly in human patients and experimental animal subjects during their early developmental period.

GWAS research identifies numerous common genetic variants which together account for most heritability in populations yet each variant produces only a small increase in disease susceptibility [7]. Research indicates that ASD risk exists on a genetic spectrum because rare high-penetrance mutations combine with common low-effect alleles.

2.2. Population Diversity and Gene Discovery

Recent population-specific exome studies have added new genes to the worldwide ASD gene database. The majority of big datasets originated from European populations yet East Asian sequencing projects have discovered genetic variants which exist in both common and exclusive forms between populations [8]. A major Chinese whole-exome sequencing study found two new ASD risk genes CIC and KMT2C which had not been identified in Western populations before. The study results show that scientists need to obtain genomic information from various populations because ancestral genetic variations between groups may conceal shared biomarkers and reduce the ability to match findings between different research populations.

2.3. Genotype–Phenotype Correlation and Clinical Heterogeneity

The many different observable characteristics of ASD stem from various genetic elements that influence its development. People who have rare LoF variants or pathogenic CNVs tend to develop intellectual disability and epilepsy along with multiple medical conditions but those with ASD caused by polygenic risk tend to have less severe high-functioning symptoms [9]. The genotype-phenotype gradient shows that the number of mutations determines both the likelihood of ASD diagnosis and the severity and specific characteristics of core symptoms.

It is also be found that sex differences added more diversity to the results. Males are diagnosed roughly three to four times more often than females, and genetic analyses support a “female protective” effect (FPE), affected females carry a higher load of deleterious mutations than affected males. Studies using neuroimaging methods show that male brain systems which manage attention and social understanding become more reactive to ASD-linked genetic risk elements than female brain systems do[10]. The different genetic risk factors between males and females with ASD affect both the process of identifying genetic causes and the methods used for clinical evaluation because female underdiagnosis hides the complete range of genetic factors that contribute to ASD.

2.4. Gene–Environment Interactions

The development of neurodevelopmental disorders results from inherited genetic factors and environmental elements and maternal influences including maternal immune activation (MIA) during pregnancy which affect genetic risk factors. Research on both animals and humans shows that prenatal immune responses which produce inflammatory cytokines lead to changes in neuronal development and synapse formation that may work together with genetic predispositions to create ASD-related behavioral symptoms. Research conducted with animal subjects shows that high maternal IL-6 and IL-17a levels during pregnancy lead to cortical developmental issues which produce ASD-like social behavior problems [11]. Research studies in epidemiology show that maternal infections during mid-gestation increase the risk of ASD in children [12]. The combination of genetic factors with environmental elements produces increased phenotypic diversity which shows that ASD needs multifactorial modeling instead of genetic-only approaches.

3. Convergent Biological Pathways

The different genetic elements make it difficult to identify stable biomarkers for this condition. Plasma proteomic and metabolomic studies have shown that people with ASD have distinct biomarkers which depend on the genetic risk factors [13]. The different characteristics of these

diseases make it challenging to create diagnostic methods that work for all patients and tailored treatment plans. The numerous phenotypes which result from genetic diversity make it difficult to establish appropriate patient classification systems. The lack of stratification makes it impossible for researchers to create precise diagnostic criteria and develop targeted treatments for ASD because they require better understanding of ASD genetics.

3.1. Rsisk Gene Discovery and Omics Tools

Exome sequencing combined with copy-number variant analysis and whole-genome sequencing has enabled researchers to find multiple genes that increase the risk of developing ASD. The high-confidence genes consist of CHD8, SCN2A, SYNGAP1, SHANK3 and additional genes which play roles in synaptic scaffolding and chromatin remodeling and transcriptional regulation. The combination of multi-omic tools such as transcriptomics and epigenomics and proteomics has improved people knowledge about how risk genes express at specific times and in particular cell types during mid-fetal cortical development.

3.2. Evidence for Molecular Convergence

The wide range of genetic variations in ASD includes both rare de novo mutations and common polygenic variants yet research shows these different genetic disruptions affect only a few core biological pathways. Research using transcriptomic and proteomic and functional genomics methods shows that synaptic signaling and chromatin remodeling and ion channel regulation and immune or neuroinflammatory processes interact with each other [14].

The synaptic level demonstrates direct connections between genes which support synaptic scaffolding and genes involved in neurotransmission functions. The mutations in SHANK3, NRXN1 and CNTNAP2 genes disrupt synapse organization and E/I balance which is a fundamental pathophysiological mechanism of ASD [15]. The NMDA and AMPA receptor complexes function as repeated functional centers together with voltage-gated ion channels SCN2A and CACNA1C in human brain transcriptomes and neuronal culture models. The channels and receptors determine synaptic plasticity and cortical excitability which shows that ASD risk genes interfere with neural communication and information processing across different genetic backgrounds.

The different pathways function together through chromatin remodeling which represents a basic cellular process. The genes CHD8, ADNP and ARID1B function as primary regulators which control transcriptional networks that develop the cortex. Research studies show that CHD8 protein binds to promoter regions of various ASD-linked genes to regulate their expression during cell and neural precursor development. The loss of CHD8 or ADNP function disrupts neurodevelopmental transcriptional programs which creates a direct link between genetic variations and synaptic and circuit-level abnormalities [16].

Research now shows that immune system responses and inflammation play a role in the shared biological mechanisms that cause ASD. Transcriptomic analyses of postmortem cortical tissue reveal downregulation of neuronal genes and upregulation of microglial activation and complement signaling modules. Animal studies show that neuroinflammatory reactions either produce or reduce the first neurodevelopmental changes and the evidence for immune-related convergence becomes stronger because maternal immune activation together with cytokine signaling (IL-6, IL-17A) produces ASD-like behaviors in animal studies which connects environmental disruptions to autism-related molecular pathways [17].

Also,the research evidence demonstrates that different genetic risk factors affect common biological pathways which include synaptic integrity and transcriptional regulation and immune homeostasis to produce similar molecular changes across different genetic backgrounds.

3.3. From Heterogeneity to Convergence: Temporal and Cell-Type Specificity

Scientists now use single-cell transcriptomic and spatial multi-omics methods to study molecular convergence patterns that emerge during different developmental stages and across different cell

types. The development of ASD seems to result from time-dependent and cell-specific pathway convergence which arises from the combination of gene expression timing patterns and the developmental paths of specific neuronal and glial cells.

The developing cortex contains higher levels of ASD risk gene expression in excitatory projection neurons that primarily exist in layers II/III and V. The neurons create essential long-range corticocortical pathways which enable higher-order social and cognitive functions that typically suffer from damage in ASD. The developmental programs of cells become disrupted when CHD8, SCN2A or DYRK1A mutations occur which result in abnormal dendritic growth and axonal targeting and synaptic timing and produces early circuit-level imbalances. The mechanisms of inhibitory interneurons and astrocytes operate through distinct pathways which depend on ARX and DLX1/2 genes for GABAergic maturation and MEGF10 and C4A genes for synaptic pruning and inflammatory signaling processes [18].

Temporal convergence is equally critical. Organoid modeling studies show that ASD-related gene networks reach their peak activity during mid-fetal corticogenesis from 16 to 24 gestational weeks when neurogenesis and synaptogenesis occur at their highest levels [19]. The timing of gene expression during the sensitive developmental window has the same importance as the mutated gene because disruptions at this stage lead to abnormal cortical layering and connectivity formation. The mutations in CHD8 and TBR1 genes disrupt the expression of specific targets that exist only during early brain development which produces time-limited but progressive developmental effects [20].

The development of ASD results from multiple genetic changes that lead to molecular convergence through disrupted transcriptional and synaptic functions in particular cell types at specific developmental stages which result in faulty neural circuits that affect social cognition and sensory processing. The framework unites the different genetic variations with their common neurobiological expressions and multiple origins that produce similar results.

The translational approach to therapy development achieves greater precision through the knowledge of how different cell types and time points influence disease progression. Future ASD treatments require solutions to fix the circuit-level problems which stem from early excitatory neuron development and neuroimmune signaling processes. Single-cell omics analysis with temporal transcriptomics and functional modeling methods reveals the shared biological pathways and developmental stages which result from various genetic disruptions that cause ASD.

4. Translational Implications

4.1. Biomarkers

The identification of biomarkers for patient subtypes can be achieved through the analysis of convergent molecular signatures which include transcriptomic modules and network-level imaging markers. The selection of interventions together with prognosis evaluation must follow the recommendations based on genetic subtype or developmental trajectory classification. The potential interventions focus on three main areas which include synaptic function and the balance between excitatory and inhibitory signals and immune system pathways. Scientists are conducting research on GPCR-modulating treatments as well as NMDA/AMPA modulators and immune system regulators. The research faces three main obstacles which stem from individual differences between subjects and the timing of developmental stages and the need to adapt animal studies for human applications.

4.2. Future Directions

Future studies need to combine long-term multi-omic data collection with single-cell analysis and imaging techniques and computational modeling approaches. The identification and stratification methods of early diagnosis enable precision medicine to develop customized treatment approaches through the connection of interventions to specific molecular and neurodevelopmental characteristics of each individual.

5. Conclusion

The various genetic variations in ASD produce distinct biological effects which share common characteristics. The development of ASD results from numerous genetic variants that interfere with essential biological mechanisms which regulate synaptic connections and transcriptional processes and neuroimmune system equilibrium. The process of convergence follows particular time patterns which affect specific cell types to create permanent neural circuit changes when developmental stages are disrupted. Research into shared mechanisms between molecular genetics and clinical practice allows scientists to establish early detection systems and biomarkers and create individualized treatment approaches. Future research using multi-omic data with longitudinal and functional analysis methods will enable the conversion of ASD convergence-based findings into practical clinical benefits for ASD patients.

References

[1] Sauer, Ann Katrin, et al. "Autism Spectrum Disorders: Etiology and Pathology." PubMed, edited by Andreas M. Grabrucker, Exon Publications, 20 Aug. 2021, www.ncbi.nlm.nih.gov/books/NBK573613/. Accessed 14 Oct. 2025.

[2] Committee to Evaluate the Supplemental Security Income Disability Program for Children with Mental Disorders, et al. "Mental Disorders and Disabilities among Low-Income Children." PubMed, edited by Thomas F. Boat and Joel T. Wu, National Academies Press (US), 2015, www.ncbi.nlm.nih.gov/books/NBK332882/. Accessed 14 Oct. 2025. Santomauro, Damian F., et al.

[3] Yim, Kristina M., et al. "Cell-Type-Specific Dysregulation of Gene Expression due to Chd8 Haploinsufficiency during Mouse Cortical Development." Cell Genomics, vol. 0, no. 0, Elsevier, Sept. 2025, https://doi.org/10.1016/j.xgen.2025.100986. Accessed 14 Oct. 2025.

[4] Bailey, A., et al. "Autism as a Strongly Genetic Disorder: Evidence from a British Twin Study." Psychological Medicine, vol. 25, no. 01, Jan. 1995, p. 63, https://doi.org/10.1017/s0033291700028099. Accessed 14 Oct. 2025.

[5] Jain, Rakesh K., et al. "Measuring Vascular Permeability in Mice." Cold Spring Harbor Protocols, vol. 2013, no. 5, Jan. 2013, pp. 444–46, https://doi.org/10.1101/pdb.prot074344.

[6] Zhu, Haiyan, et al. "A Common Polymorphism Decreases Low-Density Lipoprotein Receptor Exon 12 Splicing Efficiency and Associates with Increased Cholesterol." Human Molecular Genetics, vol. 16, no. 14, Oxford University Press, May 2007, pp. 1765–72, https://doi.org/10.1093/hmg/ddm124. Accessed 30 Apr. 2025.

[7] Callaway, Ewen. "Siberia's Ancient Ghost Clan Starts to Surrender Its Secrets." Nature, vol. 566, no. 7745, Feb. 2019, pp. 444–46, https://doi.org/10.1038/d41586-019-00672-2. Accessed 14 Oct. 2025.

[8] Zlotnick, Cheryl, and Inbal Manor-Lavon. "Resilience, Optimism and Posttraumatic Growth in First-Time Mothers." Research in Nursing & Health, no. 10.1002/nur.22338, Wiley-Blackwell, Sept. 2023, https://doi.org/10.1002/nur.22338.

[9] Satterstrom, F. Kyle, et al. "Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism." Cell, vol. 180, no. 3, Feb. 2020, pp. 568-584.e23, https://doi.org/10.1016/j.cell.2019.12.036.

[10] Stahl, Ronny, et al. "Trnp1 Regulates Expansion and Folding of the Mammalian Cerebral Cortex by Control of Radial Glial Fate." Cell, vol. 153, no. 3, Apr. 2013, pp. 535–49, https://doi.org/10.1016/j.cell.2013.03.027.

[11] The Global Epidemiology and Health Burden of the Autism Spectrum: Findings from the Global Burden of Disease Study 2021." The Lancet Psychiatry, vol. 12, no. 2, Elsevier BV, Dec. 2024, https://doi.org/10.1016/s2215-0366(24)00363-8. Accessed 14 Oct. 2025.

[12] Sigoillot, Séverine M., et al. "ColQ Controls Postsynaptic Differentiation at the Neuromuscular Junction." Journal of Neuroscience, vol. 30, no. 1, Jan. 2010, pp. 13–23, https://doi.org/10.1523/JNEUROSCI.4374-09.2010. Accessed 14 Oct. 2025.

[13] Wang, Yating, et al. “Proteomic and Metabolomic Analysis of Plasma for Pain at Different Labor Stages.” Talanta, vol. 282, Elsevier, Sept. 2024, p. 126905, https://doi.org/10.1016/j.talanta.2024.126905.

[14] Jian Ping Gong, et al. “Fine Mapping and Identification of BMI Loci in African Americans.” American Journal of Human Genetics, vol. 93, no. 4, Elsevier BV, Oct. 2013, pp. 661–71, https://doi.org/10.1016/j.ajhg.2013.08.012. Accessed 15 Oct. 2025.

[15] Abhijith Punnappurath, et al. “Face Recognition across Non-Uniform Motion Blur, Illumination, and Pose.” IEEE Transactions on Image Processing, vol. 24, no. 7, Institute of Electrical and Electronics Engineers, July 2015, pp. 2067–82, https://doi.org/10.1109/tip.2015.2412379. Accessed 15 Oct. 2025.

[16] Behera, Priyamadhaba, et al. “Control of Scabies in a Tribal Community Using Mass Screening and Treatment with Oral Ivermectin -A Cluster Randomized Controlled Trial in Gadchiroli, India.” PLOS Neglected Tropical Diseases, edited by Arunasalam Pathmeswaran, vol. 15, no. 4, Apr. 2021, p. e0009330, https://doi.org/10.1371/journal.pntd.0009330. Accessed 15 Oct. 2025.

[17] Choi, G. B., et al. “The Maternal Interleukin-17a Pathway in Mice Promotes Autism-like Phenotypes in Offspring.” Science, vol. 351, no. 6276, Jan. 2016, pp. 933–39, https://doi.org/10.1126/science.aad0314. Accessed 15 Oct. 2025.

[18] Stappers, Mark H. T., et al. “Recognition of DHN-Melanin by a C-Type Lectin Receptor Is Required for Immunity to Aspergillus.” Nature, vol. 555, no. 7696, Feb. 2018, pp. 382–86, https://doi.org/10.1038/nature25974. Accessed 15 Oct. 2025.

[19] Goodwin, Robin, et al. “Psychological Distress and Prejudice Following Terror Attacks in France.” Journal of Psychiatric Research, vol. 91, Aug. 2017, pp. 111–15, https://doi.org/10.1016/j.jpsychires.2017.03.001. Accessed 15 Oct. 2025.

[20] Zhou, Qiangjun, et al. “The Primed SNARE–Complexin–Synaptotagmin Complex for Neuronal Exocytosis.” Nature, vol. 548, no. 7668, Aug. 2017, pp. 420–25, https://doi.org/10.1038/nature23484. Accessed 15 Oct. 2025.